Article Contents ::
Details About Generic Salt :: Leuprolide
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| 8B. PITUITARY HORMONES/GONADOTROPINS in 8. ENDOCRINE/STEROID HORMONES & METABOLIC SYSTEM |
| LEUPROLIDE |
| GNRH ANALOG | ANTI-NEOPLASTIC |
| also comes under 18A. Anti-Neoplastic Agents in 18. Anti-Neoplastic Agents, |
| PK: A: Well absorbed (SC/IM) D: 27 L (Vd) E: Urine |
|
Indications & Dose: ADVANCED PROSTATE CANCER IM/SC Adult Palliative treatment: Depot preparation: 7.5mg monthly or 22.5mg q3months or 30mg q4monthsTo avoid the risk of disease flare: Cyproterone may be given for several days prior to leuprorelin therapy 3 wks | SC Adult Palliative treatment: 1mg/day as single doseTo avoid the risk of disease flare: Cyproterone may be given for several days prior to leuprorelin therapy 3 wks | AS PREPARATION FOR ENDOMETRIAL ABLATION /RESECTION IM/SC Adult Depot inj: 3.75mg 5-6 wks prior to procedure | AS PREPARATION FOR UTERINE FIBROIDS SURGERY IM/SC Adult Depot inj: 3.75mg monthly for 3-4 months before surgery | BREAST CANCER IM Adult 3.75mg q28days or 11.25mg q3months | ENDOMETRIOSIS IM Adult Depot Inj: 3.75mg/month or 11.25mg q3 months, start treatment during first 5 days of menstrual cycle & continued for up to 6 months | PRECOCIOUS PUBERTY IM Adult Depot Inj: 300µg/kg q4wk, adjust according to response | SC Adult 50µg/kg/day, adjust according to response | RADIOTHERAPY IN HIGH-RISK LOCALISED/LOCALLY ADVANCED PROSTATE CANCER Adjuvant therapy IM/SC Adult 3.75mg once a month | UTERINE FIBROIDS IM/SC Adult Depot Inj: 3.75mg/month or alternatively 11.25mg q3months |
| Contra: hypersensitivity, undiagnosed abnormal vaginal bleeding
Precautions: Decreased bone density, endometriosis, psychiatric illness, prostate cancer ADR: Serious: pituitary apoplexy, spinal cord compression, tumor flare, bone pain, hematuria, bladder outlet obstruction, neuropathy, vasodilation, angina, arrhythmia, atrial fibrillation, blood disorders, abnormal LFTs, Others: myalgia, abnormal menses, nervousness, confusion, vomiting, weight gain, headache, depression, insomnia, fatigue, dizziness/vertigo, hot flashes, testicular atrophy, hyperlipidemia, flu-like syndrome, rash, seborrhea, vaginitis, Inj site reaction, alopecia, cervix disorder, epistaxis, gynecomastia, headache, nausea, nervousness, peripheral edema, syncope DDI: Serious Antidiabetics therapeutic efficacy is reduced Monitor: BMD, hormone levels, glucose levels, cardiac monitoring |